BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 37263673)

  • 1. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
    Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
    J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
    Xiong A; Li W; Li X; Fan Y; Ma Z; Fang J; Xie Q; Zhuang W; Kang M; Wang J; Xu T; Xu M; Zhi L; Liu Q; Wang N; Zhou C
    Eur J Cancer; 2023 Sep; 190():112936. PubMed ID: 37393762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
    Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
    Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
    Wang C; Yu X; Wang W
    Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
    Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
    Li Q; Liu J; Zhang Q; Ouyang Q; Zhang Y; Liu Q; Sun T; Ye F; Zhang B; Xia S; Zhang B; Xu B
    Nat Commun; 2024 Feb; 15(1):1015. PubMed ID: 38310192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
    Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
    Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
    JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
    Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
    BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
    Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ
    Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
    Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
    Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.